scm logo

The public offering stock subscription rate of SCM Life Science Co., Ltd. (CEO Lee Byung-gun, hereinafter SCM Life Science), a bio company specializing in cell therapy development ahead of listing on the KOSDAQ, recorded a competition rate of 814.91 to 1.

Korea Investment & Securities, which organizes the listing of SCM Life Science, said, "As a result of receiving subscriptions from ordinary investors for two days on the 8th and 9th, 293,368,690 subscriptions were received for 360,000 shares, or 20% of the total number of public offering shares, and about 2.4936 trillion won was collected."

On the 2nd and 3rd, SCM Life Science conducted a demand forecast for institutional investors for 1,440,000 shares, 80% of the total 1,800,000 shares, and confirmed the public offering price at 17,000 won, the top of the band (14,000 won to 17,000 won).

At that time, a total of 1,235 domestic and foreign demand forecasts participated in the competition rate, recording a high competition rate of 1,032.17 to 1, and continued to make public offerings, further raising expectations for listing. The scheduled listing date is on the 17th.

Through this public offering, SCM Life Science will raise 30.6 billion won. Through this public offering fund, the company plans to focus on introducing clinical and new technologies at home and foreign, investing in overseas affiliates, expanding GMP facilities and production facilities, and expanding the global market.

Lee Byung-gun, CEO of SCM Life Science, said, "I would like to thank investors for trusting the company's potential and growth potential and interesting in subscriptions. With the listing, we will become a leading company in the domestic and foreign bio markets and contribute to improving the quality of life of human welfare and incurable patients around the world." In particular, we will focus on expanding corporate performance based on successful commercialization and repay investors through active shareholder-friendly policies, he stressed.

SCM Life Science was established in 2014 as a company specializing in research and development of new bio-new drugs such as next-generation high-purity "stem cell therapy" based on layer separation culture and "immune cell therapy" using dendritic cells and homogeneous CAR-CIK-CD19.

The company is expected to further boost corporate value and competitiveness based on strengths such as △ competitiveness of core original technology △ expertise of excellent research personnel △ innovation and growth of pipelines △ accumulated clinical know-how △ wide global network △ advanced system of production management and quality management.